Table 9.
Association between obesity and adipose tissue-related biomarkers in patients with adenomatous polyps
| Men |
Women |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Individuals with AP (n = 68) | Individuals without AP (n = 61) | OR (95% CI) | p | Individuals with AP (n = 48) | Individuals without AP (n = 76) | OR (95% CI) | p | ||
| Adiponectin (µm/ml) | |||||||||
| Quartile 1 | 17 (25.0) | 15 (24.6) | 1 | 10 (20.8) | 21 (27.6) | 1 | |||
| Quartile 2 | 18 (26.5) | 15 (24.6) | 1.06 (0.40–2.81) | 0.91 | 13 (27.1) | 18 (23.7) | 1.52 (0.54–4.28) | 0.43 | |
| Quartile 3 | 14 (20.6) | 18 (29.5) | 0.69 (0.26–1.84) | 0.45 | 13 (27.1) | 18 (23.7) | 1.52 (0.54–4.28) | 0.43 | |
| Quartile 4 | 19 (27.9) | 13 (21.3) | 1.29 (0.48–3.47) | 0.61 | 12 (25.0) | 19 (25.0) | 1.33 (0.47–3.77) | 0.6 | |
| p trend | 0.84 | 0.62 | |||||||
| Leptin (ng/ml) | |||||||||
| Quartile 1 | 12 (17.6) | 20 (32.8) | 1 | 11 (22.9) | 20 (26.3) | 1 | |||
| Quartile 2 | 18 (26.5) | 15 (24.6) | 2.00 (0.74–5.39) | 0.17 | 6 (12.5) | 25 (32.9) | 0.44 (0.14–1.39) | 0.15 | |
| Quartile 3 | 16 (23.5) | 16 (26.2) | 1.67 (0.62–4.51) | 0.31 | 15 (31.3) | 20 (26.3) | 1.36 (0.50–3.69) | 0.54 | |
| Quartile 4 | 22 (32.4) | 10 (16.4) | 3.67 (1.30–10.3) | 0.01 | 16 (33.3) | 11 (14.5) | 2.65 (0.91–7.66) | 0.07 | |
| p trend | 0.02 | 0.02 | |||||||
| HOMA-IR | |||||||||
| Quartile 1 | 15 (22.1) | 18 (29.5) | 1 | 11 (22.9) | 20 (26.3) | 1 | |||
| Quartile 2 | 18 (26.5) | 14 (22.9) | 1.54 (0.58–4.11) | 0.38 | 10 (20.8) | 21 (27.6) | 0.87 (0.30–2.48) | 0.79 | |
| Quartile 3 | 16 (23.5) | 17 (27.9) | 1.13 (0.43–2.97) | 0.81 | 14 (29.2) | 17 (22.4) | 1.50 (0.54–4.16) | 0.44 | |
| Quartile 4 | 19 (27.9) | 12 (19.7) | 1.90 (0.70–5.15) | 0.2 | 13 (27.1) | 18 (23.7) | 1.31 (0.47–3.66) | 0.6 | |
| p trend | 0.32 | 0.41 | |||||||
AP, adenomatous polyp; HOMA-IR, homeostatic model assessment of insulin resistance.